Previous Close | 0.5872 |
Open | 0.5899 |
Bid | 0.5310 x 1000 |
Ask | 0.5873 x 1800 |
Day's Range | 0.5300 - 0.5899 |
52 Week Range | 0.4600 - 3.7200 |
Volume | |
Avg. Volume | 53,880 |
Market Cap | 10.379M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.0040 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 7.50 |
ZURICH, SWITZERLAND / ACCESSWIRE / June 10, 2022 / NLS Pharmaceutics Ltd. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a period of 180 calendar days to regain compliance with the minimum bid price requirement.
ZURICH, SWITZERLAND / ACCESSWIRE / June 6, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP),(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that Chad C.
Additionally, the Company reports that enrollment and ongoing patient dosing in its OLE study for Quilience monotherapy continue to exhibit favorable trends."With patient enrollment now complete, we remain on track to report top-line efficacy and safety results from our Phase 2a narcolepsy trial for Quilience during the ESRS conference in late September," said Alex Zwyer, Chief Executive Officer of NLS Pharmaceutics.